Cargando…
Quantitative Insight in Utilizing Circulating Angiogenic Factors as Biomarkers for Antiangiogenic Therapy: Systems Pharmacology Approach
Circulating angiogenic factors (CAF) like vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and sVEGFR2 have potential as biomarkers for antiangiogenic therapy. The interpretation of changes in CAF is complicated by the dynamic nature of the tumor and host cells emanating CA...
Autores principales: | Sharan, S, Woo, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474166/ https://www.ncbi.nlm.nih.gov/pubmed/25295574 http://dx.doi.org/10.1038/psp.2014.36 |
Ejemplares similares
-
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities
por: Sharan, Satish, et al.
Publicado: (2015) -
Disrupted Balance of Angiogenic and Antiangiogenic Signalings in Preeclampsia
por: Furuya, Mitsuko, et al.
Publicado: (2011) -
Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma
por: Sasamura, H, et al.
Publicado: (2002) -
The pharmacological bases of the antiangiogenic activity of paclitaxel
por: Bocci, Guido, et al.
Publicado: (2013) -
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
por: Brown-Glaberman, Ursa, et al.
Publicado: (2016)